France
MaaT Pharma, a Lyon-based biotechnology firm established in 2014, is a trailblazer in developing innovative gut microbiome-driven therapies for immunomodulation in oncology. With the slogan "Boosting Survival Through Innovative Immune Modulation", the company is dedicated to enhancing cancer patient survival through their high-diversity, standardized drug candidates developed via proprietary pooling and co-cultivation technologies.
The company is distinguished by its late-stage clinical status and is well-positioned in the market as the first to bring microbiome-driven immunomodulators for oncology. Listed on Euronext Paris under the ticker MAAT since 2021, MaaT Pharma underscores its commitment to global patient betterment with a team focused on pioneering advances in healthcare.
In its latest financial move, the company secured a €9.10M Post Ipo Equity investment as of 01 November 2025, reflecting investor confidence in its growth prospects and the therapeutic promise of its drug candidates.
